利拉鲁肽对新诊断2型糖尿病合并肥胖/超重男性病人的血睾酮水平的影响被引量：9

Effect of liraglutide on the plasma testosterone level in T2DM male patiens complicated with obesity/overweight

在线阅读下载PDF

导出

摘要目的:探讨皮下注射利拉鲁肽注射液治疗新诊断2型糖尿病(T2DM)合并肥胖/超重男性病人对血浆睾酮水平的影响。方法:入组新诊断肥胖/超重T2DM男性病人40例,随机分为在原治疗方案的基础上加用利拉鲁肽20例(观察组)和不加用利拉鲁肽20例(对照组),治疗6个月,观察利拉鲁肽注射液的临床疗效和对血浆睾酮的水平变化的影响。结果:治疗前2组空腹血糖(FPG)、糖化血红蛋白(Hb A1c)、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)差异均无统计学意义(P>0.05)。治疗后,对照组FPG和Hb A1c较治疗前明显改善(P<0.01),观察组各项指标均较治疗前明显改善(P<0.01);且与对照组比较,观察组FPG和Hb A1c均降低(P<0.05和P<0.01),HOMA-β明显升高(P<0.01)。治疗后观察组睾酮水平明显高于治疗前(P<0.01),而对照组治疗前后睾酮水平差异无统计学意义(P>0.05);治疗前后,2组睾丸酮水平间差异均无统计学意义(P>0.05)。结论:利拉鲁肽能有效降低新诊断T2DM合并肥胖/超重病人血糖,改善胰岛β细胞功能,可提高血浆睾酮水平。 Objective： To investigate the effects of liraglutide on the plasma testosterone level in type 2 diabetes mellitus（T2DM） male patients complicated with obesity/overweight.Methods： A total of 40 obese or overweight T2DM patients were randomly divided into the control group and observation group（20 cases each group）.The control group and observation group were treated with routine method and liraglutide combined with routine method,respectively.After 6 months of treatment,the clinical effiency of liraglutide,and effect of liraglutide on the plasma testosterone level were observed.Results： Before treatment,the differences of the levels of FPG,HbA1c,HOMA-IR and HOMA-β between two groups were not statistically significant（ P 〉0.05）.After treatment,the levels of FPG and HbA1c in control group,and all indexes in observation group were significantly improved compared with before treatment（ P 〈 0.01 ）.Compared with the control group,the levels of FPG and HbA1c,and level of HOMA-β in observation group significantly decreased and increased after treatment,respectively（ P 〈0.05 to P 〈0.01）.The plasma level of testosterone in observation group after treatment was significantly higher than that before treatment（ P 〈0.01）,and the difference of which in control group between before and after treatment was not statistically significant（ P 〉0.05）.The differences of the plasma levels of testosterone between two groups were not statistically significant before and after treatment（ P 〉0.05）.Conclusions： Liraglutide can effectively reduce the blood glucose,improve the function of pancreas islet β-cells,and enhance the plasma level of testosterone in T2DM patients complicated with obesity or overweight.

作者赵琳刘洋申晶 ZHAO Lin;LIU Yang;SHEN Jing(Department of Endocrinololy,The 309th PLA Hospital,Beijing 100091,China)

机构地区解放军第

出处《蚌埠医学院学报》 CAS 2018年第4期501-502,506,共3页 Journal of Bengbu Medical College

关键词 2型糖尿病利拉鲁肽睾酮肥胖超重 type 2 diabetes mellitus liraglutide testosterone obesity overweight

分类号 R587.1 [医药卫生—内分泌]

作者简介赵琳（1979鄄）,女,博士,主治医师.;[通信作者]申晶,博士,副主任医师.E鄄mail：shenjingshenhua@126.com

引文网络
相关文献

参考文献4

1安雅莉,高妍,朱倩,宁光,贾伟平,黄勤,许雯,李成江,周智广,施秉银,单忠艳,陈璐璐,许樟荣,王妲,严励,钟惠菊,姬秋和,李红,薛元明,张木勋,谷卫,郭晓蕙,高蕾丽,洪洁,刘芳,邹大进,李延兵,张小英,李桢,郭辉,赵晓娟,吴汉妮,王玉珍,赵维纲,张少玲,吴静,张南雁,杨凤英,张云,周鑫荣,任跃忠,李光伟.不同体重指数新诊断2型糖尿病患者胰岛素分泌和胰岛素抵抗状况调查[J].中华医学杂志,2009,89(16):1117-1121. 被引量：21
2中国2型糖尿病合并肥胖综合管理专家共识[J].中华内分泌代谢杂志,2016,32(8):623-627. 被引量：152
3姚亚妮,朱枣兰,王玉玲.利拉鲁肽联合盐酸二甲双胍治疗维吾尔族与汉族肥胖2型糖尿病的临床疗效[J].新疆医科大学学报,2015,38(12):1527-1530. 被引量：12
4杜益君,潘天荣,钟兴,刘妮娜,张萍.利拉鲁肽治疗不同2型糖尿病病程肥胖/超重患者的临床疗效及安全性观察[J].中国糖尿病杂志,2015,23(12):1066-1069. 被引量：19

二级参考文献40

1李琳琳,毛新民,张月明,冉新建,努丽曼,周康,杜景玉,杨永新,邬利娅,白丽,卡德尔,王赛刚,林仁勇,李念东.新疆地区维吾尔族、哈萨克族2型糖尿病代谢特征与饮食结构分析[J].中华内分泌代谢杂志,2005,21(2):141-142. 被引量：55
2Anderson JW, Kendall CW, Jenkins DJ, et al. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coil Nutr, 2003, 22: 331-339.
3Li GW, Lillioja S, Peter H, et al. Introduction of a new index of insulin sensitivity. In proceedings of the 15th international diabetes federation congress, Kobe J, 1994, (Abstract) 1994, 489. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1987, 28: 412-416.
4Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of non-insulin dependent diabetes mellitus in Mexican-Americans. Diabetes, 1995, 44: 1386-1391.
5Zimmet P. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity and demography. Diabetes Care, 995, 18 : 1050-1064.
6Park JY, Lee Ku, Kim HK, et al. Past and current obesity in Koreans with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract, 1997, 35: 49-56.
7United Kingdom Prospective Diabetes Study Group. United kingdom prospective diabetes study 24: a 6-year randomized, controlled trial comparing sultbnyurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med, 1998, 128: 165-175.
8Roy MN, Biswas KB, Siddiqua N, et al. Determinants of insulin secretion and sensitivity in bangladeshi type 2 diabetic subjects. Metab Syndr Relat Disord, 2007, 5: 275-281.
9Yki-Jarvinen H. Toxity of hyperglycemia in type 2 diabetes. Diabetes Metab Rev,1998, 14: s45-s50.
10Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1987, 28: 412-416.